Perspective Therapeutics, Inc. beat EPS estimates 100% of the time across 2 reported quarters (2 beats, 0 misses), averaging +16.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.27 | $-0.22 | +18.5% | Beat | |
| Q1 FY26 | $-0.29 | $-0.25 | +13.8% | Beat |
Back to CATX overview · CATX holders · CATX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.